Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

Analysis of 4 RCTs (n=3623) found bempedoic acid decreased LDL-C by 18% vs placebo when added to maximally tolerated statins in patients with atherosclerotic CVD or heterozygous familial hypercholesterolemia or both, but was linked to more frequent increased uric acid and gout.


JAMA Cardiology